Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Cytoki Pharma logo — Leveraging lipidated IL-22 to treat metabolic diseases and I...

Cytoki Pharma

Leveraging lipidated IL-22 to treat metabolic diseases and IBD

Founded 2019 Denmark Denmark 4 employees Series A Total: $45.00M Biotechnology, Life Sciences

General Information

Company Name Cytoki Pharma
Founded Year 2019
Location Denmark Denmark
Employees 4
Industries Biotechnology, Life Sciences
Funding Stage Series A
Business Model B2B, B2B2C
Revenue Model Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Cytoki Pharma. To contact Cytoki Pharma, visit cytokipharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cytoki Pharma compare?

A PDF of Cytoki Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cytoki Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cytoki Pharma

Cytoki Pharma, founded in 2019, is a pioneering clinical-stage biotechnology company based in Denmark. Specializing in the development of novel medicines, the company is leveraging lipidated IL-22 to target both metabolic diseases and inflammatory bowel disease (IBD). Their innovative approach positions them as a cutting-edge player within the Biotechnology and Life Sciences industries.

In May 2021, Cytoki Pharma secured a significant $45.00M Series A investment, underscoring strong investor confidence. This funding round was led by notable investors including Seventure Partners, ND Capital, Ysios Capital, and Lundbeckfonden Emerge. The financial backing is a strong testament to the market potential and scientific promise of their unique approach to treating prevalent and challenging health conditions.

Business keywords: clinical stage, metabolic diseases, inflammatory bowel disease (IBD), epithelial injury, immune system modulation, cytokine therapy, IL-22 biology, protein engineering, long-acting proteins, novel medicines, unmet medical needs, drug development, organ injury treatment

Services & Products

Development of IL-22 analogues
Phase 2 clinical evaluation of CK-10045
Creation of therapies for metabolic and epithelial-related diseases

Target Customers

Patients with metabolic diseases Individuals suffering from obesity People with type 2 diabetes Patients with inflammatory bowel disease Healthcare professionals in metabolic and inflammatory diseases

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $45.00M 4
Seventure Partners ND Capital Ysios Capital
Seventure Partners, ND Capital +2
04 May 2021

Cytoki Pharma Alternatives & Competitors

View All Alternatives
Cytoki Pharma vs
Simcha Therapeutics
Simcha Therapeutics United States

Overcoming biological challenges in clinically translatable pathways.

Series B
15 employees
Biotechnology, Health and Wellness
Cytoki Pharma vs
Entact Bio
Entact Bio United States

Creating new medicines by enhancing protein function

Venture round
42 employees
Biopharma, Biotechnology
Cytoki Pharma vs
Tridek-One
Tridek-One France

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

Venture round
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About Cytoki Pharma

Leveraging lipidated IL-22 to treat metabolic diseases and IBD
Cytoki Pharma was founded in 2019.
Cytoki Pharma is headquartered in Denmark.
Cytoki Pharma operates in Biotechnology and Life Sciences. Its work centres on clinical stage, metabolic diseases, inflammatory bowel disease (IBD) and epithelial injury. Its customers include Patients with metabolic diseases, Individuals suffering from obesity and People with type 2 diabetes.
Cytoki Pharma has a B2B and B2B2C business model. Its revenue comes from Licensing and Performance Based.
Cytoki Pharma has approximately 4 employees.
Cytoki Pharma has completed 1 funding round, raising a total of $45.00M. The latest funding stage is Series A.
Cytoki Pharma offers: Development of IL-22 analogues, Phase 2 clinical evaluation of CK-10045, Creation of therapies for metabolic and epithelial-related diseases.
Top alternatives and competitors to Cytoki Pharma include Simcha Therapeutics, Entact Bio, Tridek-One, Laminar Pharma, Exalys Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cytoki Pharma and Simcha Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cytoki Pharma, https://bouncewatch.com/company/cytoki-pharma, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout